eflepedocokin alfa

recombinant fusion protein consisting of two human interleukin-22 (IL-22) molecules linked to an immunoglobulin constant region (IgG2-FC)

Also Known As:

F-652; IL-22 dimer F-652; Promenakin; recombinant human IL-22 IgG2-Fc; recombinant human interleukin-22 IgG2-Fc

Networked: 3 relevant articles (2 outcomes, 1 trials/studies)

1.	Hepatitis 01/01/2020 - "An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis."
2.	Endotoxemia 01/01/2022 - "We found that F-652 injection significantly improved the survival rates and reduced pro-inflammatory cytokines (IL-6, TNF-a, IL-1β, MCP-1) in LPS-induced endotoxemia mice. "
3.	End Stage Liver Disease 01/01/2020 - "F-652 (10 μg/kg, 30 μg/kg, or 45 μg/kg) administered on days 1 and 7 was tested in 3 patients each with moderate (Model for End-Stage Liver Disease [MELD] scores: 11-20) and severe AH (MELD scores: 21-28). "
4.	Inflammation (Inflammations) 01/01/2020 - "F-652 is safe in doses up to 45 μg/kg and associated with a high rate of improvement as determined by Lille and MELD scores, reductions in markers of inflammation and increases in markers of hepatic regeneration. "
5.	Injection Site Reaction 01/01/2019 - "Following single-dose subcutaneous (SC) injection of F-652 at 2.0 µg/kg into healthy subjects, six out of six subjects experienced delayed injection site reactions, which presented as erythematous and/or discoid eczematous lesions 10 to 17 days post-dosing. "